467 related articles for article (PubMed ID: 14984815)
21. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
[TBL] [Abstract][Full Text] [Related]
22. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
23. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
[No Abstract] [Full Text] [Related]
24. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
Ferraccioli G; Gremese E
Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
26. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
27. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
[TBL] [Abstract][Full Text] [Related]
28. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
29. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
Kekow J; Welte T; Kellner U; Pap T
Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
[No Abstract] [Full Text] [Related]
30. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
[TBL] [Abstract][Full Text] [Related]
31. [TNF antagonists in therapy of rheumatoid arthritis].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
[No Abstract] [Full Text] [Related]
32. Anti-TNFalpha therapy for rheumatoid arthritis: an update.
Taylor PC
Intern Med; 2003 Jan; 42(1):15-20. PubMed ID: 12583612
[TBL] [Abstract][Full Text] [Related]
33. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
34. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
Marchesoni A; Zaccara E; Gorla R; Bazzani C; Sarzi-Puttini P; Atzeni F; Caporali R; Bobbio-Pallavicini F; Favalli EG
Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
[TBL] [Abstract][Full Text] [Related]
35. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
36. [Anti-TNF-alpha therapy as a new option in treatment of rheumatoid arthritis?].
Leeb BF; Sautner J
Wien Med Wochenschr; 1999; 149(19-20):554-7. PubMed ID: 10637966
[TBL] [Abstract][Full Text] [Related]
37. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis.
Kuroda T; Wada Y; Kobayashi D; Murakami S; Sakai T; Hirose S; Tanabe N; Saeki T; Nakano M; Narita I
J Rheumatol; 2009 Nov; 36(11):2409-15. PubMed ID: 19797512
[TBL] [Abstract][Full Text] [Related]
38. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
40. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
Blom M; Kievit W; Fransen J; Kuper IH; den Broeder AA; De Gendt CM; Jansen TL; Brus HL; van de Laar MA; van Riel PL
J Rheumatol; 2009 Oct; 36(10):2171-7. PubMed ID: 19723902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
